REBUZZI, SARA ELENA
 Distribuzione geografica
Continente #
EU - Europa 1.719
AS - Asia 146
SA - Sud America 26
NA - Nord America 24
AF - Africa 2
Totale 1.917
Nazione #
IT - Italia 1.716
SG - Singapore 56
VN - Vietnam 41
CN - Cina 37
US - Stati Uniti d'America 18
BR - Brasile 16
AR - Argentina 5
ID - Indonesia 5
HK - Hong Kong 4
MX - Messico 4
CO - Colombia 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
CH - Svizzera 1
CL - Cile 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EC - Ecuador 1
GT - Guatemala 1
IN - India 1
SA - Arabia Saudita 1
UY - Uruguay 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 1.917
Città #
Genoa 1.201
Vado Ligure 218
Rapallo 185
Genova 106
Ho Chi Minh City 15
Ashburn 12
Beijing 11
Singapore 8
Bordighera 5
Hanoi 5
Hong Kong 4
Haiphong 3
Hải Dương 3
Da Nang 2
Guangzhou 2
Thái Nguyên 2
Bandung 1
Belford Roxo 1
Biên Hòa 1
Bình Dương 1
Bắc Ninh 1
Cachoeirinha 1
Centro Municipality 1
Chlef 1
Curitiba 1
Franca 1
Guadalupe 1
Guarulhos 1
Guatemala City 1
Itapevi 1
Iztapalapa 1
Jakarta 1
Johannesburg 1
Joinville 1
Lanús 1
Lins 1
Lucknow 1
Maceió 1
Maldonado 1
Mexico City 1
Morón 1
Mostar 1
Mucuri 1
New York 1
Ninh Bình 1
Osasco 1
Ourinhos 1
Palangkaraya 1
Pasto 1
Peruíbe 1
Phủ Lý 1
Quito 1
Rio de Janeiro 1
Riyadh 1
Río Gallegos 1
San Juan 1
Santa Marta 1
Santiago 1
Santiago de los Caballeros 1
Saquarema 1
São José do Rio Preto 1
Tashkent 1
The Bronx 1
Tianjin 1
Tây Ninh 1
Villa Ballester 1
Vinh 1
Vĩnh Long 1
Totale 1.834
Nome #
Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome? 188
MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma 156
Feasibility of multiple immunoexpression assay for immune tumor micrornvironment (I-TME) on matched metastatic and primary renal cell carcinoma (RCC) for patient prognostication and predictiveness to immunotherapy (preliminary analyses of the Meet URO 18 study). 96
Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib 95
Hyperthyroidism in non-seminomatous testicular germ cell tumors: two case reports and literature review 90
The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study) 86
Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223 84
Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study 79
Fusion 3D gross sampling method to overcome heterogeneity in clear cell renal cell carcinoma (ccRCC) and grading angiogenic versus immune signatures. 79
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study) 78
Prognostic Value of the BIO-Ra Score in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223 after the European Medicines Agency Restricted Use: Secondary Investigations of the Multicentric BIO-Ra Study 77
Beyond first-line immunotherapy: Potential therapeutic strategies based on different pattern progressions: Oligo and systemic progression 76
Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives 67
Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab 60
Systemic therapy for pre-treated malignant mesothelioma: A systematic review, meta-analysis and network meta-analysis of randomised controlled trials 59
Combined response of advanced cutaneous squamous cell carcinoma and renal cell carcinoma to immunotherapy: a case report 58
Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review 54
The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study 51
MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma 51
Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis 51
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study 50
Prognostic models for patients with metastatic urothelial carcinoma: why use them? 47
Neuroendocrine differentiation of prostate cancer is not systematically associated with increased 18f-fdg uptake 46
Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study 45
Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9) 42
The DASciS Software for BSI Calculation as a Valuable Prognostic Tool in mCRPC Treated with 223RaCl2: A Multicenter Italian Study 41
THE PROGNOSTIC ROLE OF THE IMMUNE TUMOR MICROENVIRONMENT IN METASTATIC RENAL CELL CARCINOMA PATIENTS TREATED WITH IMMUNOTHERAPY (Meet-URO 18 I-TME study) 37
The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis 37
Large Italian Multicenter Study on Prognostic Value of Baselines Variables in mCRPC Patients Treated with 223RaCl2: Ten Years of Clinical Experience 8
Totale 1.988
Categoria #
all - tutte 9.149
article - articoli 9.017
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.166


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202119 0 0 0 0 0 0 0 2 0 2 0 15
2021/202280 1 1 3 1 0 3 1 11 13 12 11 23
2022/2023216 13 15 7 26 23 19 9 30 31 6 37 0
2023/2024168 7 17 3 23 14 31 11 7 3 16 7 29
2024/2025595 53 42 15 30 64 56 44 115 32 24 64 56
2025/2026886 149 179 265 120 155 18 0 0 0 0 0 0
Totale 1.988